Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging

doi:10.3748/wjg.v13.i15.2261

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 15

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1664)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

248

HTML

1193

Figures (1-2)

223

Sum=1664

Apr 21, 2007 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Apr 21, 2007; 13(15): 2261-2262
Published online Apr 21, 2007. doi: 10.3748/wjg.v13.i15.2261

Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging

Sabri Zincirkeser, Alper Sevinc, M Emin Kalender, Celalettin Camci

Sabri Zincirkeser, Department of Nuclear Medicine, Gaziantep University, School of Medicine, Sahinbey Medical Center, Gaziantep TR-27310, Turkey

Alper Sevinc, M Emin Kalender, Celalettin Camci, Department of Medical Oncology, Gaziantep University, School of Medicine, Gaziantep Oncology Hospital, Gaziantep TR-27310, Turkey

Author contributions: All authors contributed equally to the work.

Correspondence to: Dr. Alper Sevinc, Gaziantep University, School of Medicine, Department of Medical Oncology, Gaziantep Oncology Hospital, Gaziantep TR-27310, Turkey. sevinc@gantep.edu.tr

Telephone: +90-342-4720711 Fax: +90-342-4720718

Received: December 20, 2006
Revised: December 28, 2006
Accepted: January 26, 2007
Published online: April 21, 2007

Abstract

A 41-year old female with metastatic gastrointestinal stromal tumor was referred to 18F-FDG-positron emission tomography and computed tomography (PET/CT) scan before and after one-month treatment with imatinib (Glivec^®, Gleevec^®, Novartis, Basel, Switzerland), a tyrosine kinase inhibitor (400 mg/d). Metabolic response was evaluated before and after one month of therapy. The decrease of the maximum standardised uptake value (SUV) was 79% (from 9.8 to 2.1). Positron emission tomography demonstrated complete metabolic response after one-month of imatinib treatment. Additionally, the previous lesion was compared with the coronal computerized tomographic image. There was no difference in the size of the tumor before and after therapy according to CT images. However, metabolic activity was inhibited. 18F-FDG-PET is a valuable method for the detection of response to one-month imatinib treatment in patients with gastrointestinal stromal tumors.

Keywords: 18F-fluorodeoxyglucose; Positron emission tomography; Computerized tomography; Gastrointestinal stromal tumor; Imatinib